Context Therapeutics Inc (CNTX) Actualités

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form EFFECT - Notice of Effectiveness

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form S-3 - Registration statement under Securities Act of 1933

Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results

Expands pipeline of T cell engaging bispecific antibodies through acquisitions of CT-95, a Mesothelin x CD3...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Context Therapeutics to Participate in Upcoming Investor Conferences in November

PHILADELPHIA, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq:...

Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

PHILADELPHIA, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq:...

Form 8-K - Current report

Form 8-K - Current report

Form 8-K - Current report

Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors

PHILADELPHIA, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”...

Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results

Announced acquisition of CT-95, a mesothelin x CD3 bispecific antibody Claudio Dansky Ullmann, M.D. named...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]